| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Influenza, Human | 49 | 2021 | 10779 | 3.74 | Why? |
| Influenza Vaccines | 21 | 2020 | 2941 | 3.21 | Why? |
| Influenza B virus | 9 | 2020 | 815 | 2.74 | Why? |
| Hand, Foot and Mouth Disease | 8 | 2019 | 115 | 2.32 | Why? |
| Infectious Disease Incubation Period | 9 | 2021 | 1033 | 2.06 | Why? |
| Hong Kong | 35 | 2021 | 3361 | 2.01 | Why? |
| Influenza A Virus, H3N2 Subtype | 10 | 2020 | 572 | 1.63 | Why? |
| Influenza A Virus, H1N1 Subtype | 14 | 2021 | 2984 | 1.45 | Why? |
| Respiratory Tract Infections | 8 | 2021 | 6817 | 1.28 | Why? |
| Influenza A virus | 7 | 2019 | 2234 | 1.15 | Why? |
| Seasons | 16 | 2019 | 4071 | 0.98 | Why? |
| Epidemics | 10 | 2021 | 6407 | 0.97 | Why? |
| Enterovirus | 4 | 2018 | 402 | 0.86 | Why? |
| Vaccine Potency | 2 | 2019 | 339 | 0.83 | Why? |
| Disease Outbreaks | 16 | 2021 | 27595 | 0.76 | Why? |
| Epidemiologic Studies | 2 | 2020 | 554 | 0.71 | Why? |
| Infant | 34 | 2021 | 30274 | 0.70 | Why? |
| Orthomyxoviridae | 4 | 2020 | 1168 | 0.69 | Why? |
| Child, Preschool | 38 | 2021 | 36283 | 0.68 | Why? |
| Drug Utilization Review | 1 | 2018 | 72 | 0.67 | Why? |
| Respiratory Syncytial Viruses | 2 | 2018 | 612 | 0.65 | Why? |
| Tropical Climate | 1 | 2017 | 179 | 0.64 | Why? |
| Communicable Diseases, Emerging | 3 | 2021 | 2523 | 0.61 | Why? |
| Masks | 5 | 2021 | 8528 | 0.60 | Why? |
| Statistics as Topic | 1 | 2018 | 370 | 0.58 | Why? |
| Vaccines, Inactivated | 2 | 2019 | 1562 | 0.54 | Why? |
| Child | 40 | 2021 | 70012 | 0.54 | Why? |
| Vaccination | 10 | 2020 | 19050 | 0.53 | Why? |
| Public Health | 7 | 2021 | 16359 | 0.52 | Why? |
| Hospitalization | 22 | 2021 | 54280 | 0.52 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 6 | 2020 | 8843 | 0.52 | Why? |
| Child Welfare | 1 | 2019 | 405 | 0.51 | Why? |
| Public Health Surveillance | 5 | 2020 | 3129 | 0.49 | Why? |
| Republic of Korea | 8 | 2021 | 5858 | 0.48 | Why? |
| Basic Reproduction Number | 3 | 2021 | 2676 | 0.48 | Why? |
| Patient Isolation | 5 | 2020 | 3182 | 0.46 | Why? |
| Primary Prevention | 1 | 2019 | 778 | 0.46 | Why? |
| Public Health Practice | 1 | 2020 | 945 | 0.45 | Why? |
| China | 34 | 2021 | 50654 | 0.45 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.45 | Why? |
| Humans | 120 | 2021 | 930598 | 0.44 | Why? |
| Coronavirus Infections | 31 | 2020 | 253789 | 0.44 | Why? |
| Forecasting | 4 | 2020 | 4492 | 0.42 | Why? |
| Immunization Schedule | 1 | 2018 | 1305 | 0.42 | Why? |
| Adolescent | 36 | 2021 | 86841 | 0.41 | Why? |
| Genotype | 3 | 2018 | 4697 | 0.41 | Why? |
| Health Education | 1 | 2020 | 1539 | 0.38 | Why? |
| Models, Theoretical | 5 | 2021 | 6659 | 0.38 | Why? |
| Influenza A Virus, H7N9 Subtype | 3 | 2018 | 415 | 0.37 | Why? |
| Population Surveillance | 7 | 2019 | 4967 | 0.36 | Why? |
| Enterovirus A, Human | 3 | 2019 | 180 | 0.36 | Why? |
| Male | 62 | 2021 | 367725 | 0.35 | Why? |
| Pneumonia, Viral | 23 | 2020 | 243684 | 0.35 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2017 | 1234 | 0.35 | Why? |
| Female | 59 | 2021 | 380317 | 0.34 | Why? |
| Serogroup | 3 | 2018 | 510 | 0.34 | Why? |
| Virus Shedding | 3 | 2020 | 5834 | 0.33 | Why? |
| Particulate Matter | 1 | 2019 | 3249 | 0.32 | Why? |
| Research | 1 | 2020 | 2115 | 0.32 | Why? |
| Health Knowledge, Attitudes, Practice | 5 | 2020 | 8811 | 0.32 | Why? |
| Mass Vaccination | 1 | 2017 | 1101 | 0.31 | Why? |
| History, 21st Century | 5 | 2018 | 1849 | 0.29 | Why? |
| Pandemics | 34 | 2021 | 389249 | 0.28 | Why? |
| Infant, Newborn | 12 | 2021 | 23105 | 0.27 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.27 | Why? |
| Immunization Programs | 1 | 2017 | 2006 | 0.26 | Why? |
| Young Adult | 26 | 2021 | 93724 | 0.26 | Why? |
| Health Policy | 3 | 2020 | 6242 | 0.26 | Why? |
| Environmental Microbiology | 2 | 2020 | 575 | 0.26 | Why? |
| Sentinel Surveillance | 4 | 2018 | 1093 | 0.26 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.26 | Why? |
| Aged | 34 | 2021 | 215776 | 0.26 | Why? |
| Enterovirus Infections | 2 | 2018 | 404 | 0.25 | Why? |
| Antimicrobial Stewardship | 3 | 2021 | 931 | 0.25 | Why? |
| Aged, 80 and over | 19 | 2021 | 88759 | 0.24 | Why? |
| Middle Aged | 38 | 2021 | 270681 | 0.24 | Why? |
| Cluster Analysis | 2 | 2021 | 3001 | 0.24 | Why? |
| Adult | 37 | 2021 | 244371 | 0.24 | Why? |
| Influenza in Birds | 2 | 2018 | 528 | 0.23 | Why? |
| Betacoronavirus | 19 | 2020 | 204454 | 0.22 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.22 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.21 | Why? |
| Hemagglutination | 1 | 2020 | 36 | 0.21 | Why? |
| Health Care Costs | 3 | 2019 | 1007 | 0.21 | Why? |
| Global Health | 3 | 2020 | 13911 | 0.20 | Why? |
| Penicillins | 1 | 2021 | 132 | 0.20 | Why? |
| Fluoroquinolones | 1 | 2021 | 235 | 0.20 | Why? |
| Severe Acute Respiratory Syndrome | 3 | 2015 | 12361 | 0.20 | Why? |
| Epidemiological Monitoring | 3 | 2017 | 3493 | 0.20 | Why? |
| Influenzavirus A | 1 | 2019 | 66 | 0.20 | Why? |
| Self-Examination | 1 | 2019 | 30 | 0.20 | Why? |
| Incidence | 10 | 2021 | 25622 | 0.20 | Why? |
| Ecology | 1 | 2020 | 140 | 0.20 | Why? |
| Influenza A Virus, H2N2 Subtype | 1 | 2018 | 6 | 0.19 | Why? |
| Fluorescent Antibody Technique, Direct | 1 | 2018 | 69 | 0.19 | Why? |
| Cephalosporins | 1 | 2021 | 250 | 0.19 | Why? |
| Poultry | 2 | 2018 | 437 | 0.19 | Why? |
| Chronic Disease | 1 | 2014 | 5139 | 0.19 | Why? |
| Geography, Medical | 2 | 2018 | 537 | 0.19 | Why? |
| Age Factors | 8 | 2020 | 21039 | 0.18 | Why? |
| Global Burden of Disease | 2 | 2019 | 531 | 0.18 | Why? |
| Macrolides | 1 | 2021 | 369 | 0.18 | Why? |
| Human bocavirus | 1 | 2018 | 142 | 0.18 | Why? |
| Scarlet Fever | 1 | 2017 | 35 | 0.18 | Why? |
| Dengue Vaccines | 1 | 2019 | 123 | 0.17 | Why? |
| Severity of Illness Index | 6 | 2020 | 48226 | 0.17 | Why? |
| Adenoviridae Infections | 1 | 2018 | 150 | 0.17 | Why? |
| Air | 1 | 2018 | 145 | 0.17 | Why? |
| Streptococcus pyogenes | 1 | 2017 | 118 | 0.16 | Why? |
| Disease Transmission, Infectious | 4 | 2020 | 9044 | 0.16 | Why? |
| Epidemiologic Research Design | 1 | 2018 | 166 | 0.16 | Why? |
| Parvoviridae Infections | 1 | 2018 | 222 | 0.16 | Why? |
| Models, Statistical | 4 | 2020 | 5312 | 0.16 | Why? |
| Neuraminidase | 1 | 2019 | 289 | 0.16 | Why? |
| Cross Protection | 1 | 2019 | 373 | 0.16 | Why? |
| Case-Control Studies | 7 | 2019 | 17671 | 0.16 | Why? |
| Exhalation | 1 | 2020 | 441 | 0.16 | Why? |
| Patient Outcome Assessment | 1 | 2020 | 707 | 0.16 | Why? |
| Coronavirus | 5 | 2020 | 18339 | 0.16 | Why? |
| Travel-Related Illness | 2 | 2021 | 1357 | 0.15 | Why? |
| Metapneumovirus | 1 | 2018 | 465 | 0.15 | Why? |
| Asia, Southeastern | 1 | 2017 | 390 | 0.15 | Why? |
| Paramyxoviridae Infections | 1 | 2018 | 364 | 0.15 | Why? |
| Morbidity | 2 | 2018 | 1426 | 0.14 | Why? |
| Urban Health | 1 | 2018 | 382 | 0.14 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.14 | Why? |
| Seroepidemiologic Studies | 4 | 2019 | 10017 | 0.14 | Why? |
| Contact Tracing | 4 | 2021 | 8448 | 0.14 | Why? |
| Disease Notification | 2 | 2017 | 639 | 0.14 | Why? |
| Pharynx | 2 | 2021 | 1544 | 0.14 | Why? |
| Immunization, Secondary | 2 | 2020 | 1649 | 0.14 | Why? |
| Linear Models | 3 | 2019 | 1914 | 0.13 | Why? |
| Transportation | 1 | 2020 | 691 | 0.13 | Why? |
| Time Factors | 8 | 2020 | 31397 | 0.13 | Why? |
| Nasal Cavity | 1 | 2019 | 909 | 0.13 | Why? |
| Regression Analysis | 2 | 2018 | 2484 | 0.13 | Why? |
| Hygiene | 1 | 2020 | 987 | 0.13 | Why? |
| Respiration Disorders | 1 | 2019 | 526 | 0.13 | Why? |
| Oropharynx | 2 | 2021 | 1581 | 0.12 | Why? |
| Risk Assessment | 5 | 2020 | 25439 | 0.12 | Why? |
| Immunogenicity, Vaccine | 2 | 2020 | 4624 | 0.12 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.12 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.12 | Why? |
| Parathyroid Hormone | 1 | 2012 | 98 | 0.12 | Why? |
| Rhinovirus | 1 | 2018 | 979 | 0.12 | Why? |
| Vaccines, Attenuated | 1 | 2018 | 952 | 0.12 | Why? |
| Air Microbiology | 2 | 2019 | 1322 | 0.12 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.12 | Why? |
| Adenoviridae | 1 | 2018 | 1151 | 0.12 | Why? |
| Models, Biological | 2 | 2020 | 4907 | 0.12 | Why? |
| Vaccines | 2 | 2021 | 3692 | 0.12 | Why? |
| Dengue Virus | 1 | 2019 | 910 | 0.12 | Why? |
| Quarantine | 5 | 2021 | 18418 | 0.11 | Why? |
| Cross Infection | 3 | 2019 | 8675 | 0.11 | Why? |
| Immunity | 2 | 2020 | 2651 | 0.11 | Why? |
| Nose | 1 | 2017 | 1093 | 0.11 | Why? |
| Orthomyxoviridae Infections | 1 | 2018 | 1001 | 0.11 | Why? |
| Thyroidectomy | 1 | 2012 | 207 | 0.10 | Why? |
| Diagnostic Tests, Routine | 2 | 2019 | 2643 | 0.10 | Why? |
| Research Design | 2 | 2018 | 5830 | 0.10 | Why? |
| False Negative Reactions | 1 | 2017 | 1785 | 0.10 | Why? |
| Cost-Benefit Analysis | 2 | 2021 | 2259 | 0.10 | Why? |
| Ozone | 1 | 2018 | 757 | 0.10 | Why? |
| New Zealand | 1 | 2017 | 2073 | 0.10 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.09 | Why? |
| Animals | 10 | 2021 | 78931 | 0.09 | Why? |
| Carrier State | 1 | 2020 | 2100 | 0.09 | Why? |
| Bayes Theorem | 2 | 2015 | 3237 | 0.09 | Why? |
| Swine Diseases | 1 | 2018 | 1219 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Age Distribution | 4 | 2019 | 3567 | 0.09 | Why? |
| Saudi Arabia | 2 | 2016 | 4423 | 0.09 | Why? |
| Gastrointestinal Microbiome | 1 | 2021 | 1961 | 0.09 | Why? |
| Asymptomatic Diseases | 2 | 2020 | 3444 | 0.09 | Why? |
| World Health Organization | 2 | 2021 | 4213 | 0.09 | Why? |
| Environmental Monitoring | 1 | 2020 | 3143 | 0.09 | Why? |
| Family Characteristics | 1 | 2018 | 2551 | 0.09 | Why? |
| Anxiety Disorders | 1 | 2020 | 2290 | 0.08 | Why? |
| Logistic Models | 3 | 2020 | 9089 | 0.08 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.08 | Why? |
| Urban Population | 1 | 2017 | 2000 | 0.08 | Why? |
| Thyroid Neoplasms | 1 | 2012 | 422 | 0.08 | Why? |
| Databases, Factual | 3 | 2019 | 6248 | 0.08 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.08 | Why? |
| Immunologic Memory | 1 | 2019 | 3362 | 0.08 | Why? |
| Dengue | 1 | 2019 | 1565 | 0.08 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.08 | Why? |
| Travel | 3 | 2021 | 7220 | 0.08 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.08 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.08 | Why? |
| Treatment Outcome | 5 | 2019 | 51732 | 0.08 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.08 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.08 | Why? |
| Frailty | 1 | 2017 | 1432 | 0.07 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.07 | Why? |
| Specimen Handling | 2 | 2021 | 6190 | 0.07 | Why? |
| Feces | 1 | 2018 | 4235 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.07 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 11367 | 0.07 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.07 | Why? |
| Parents | 1 | 2018 | 2758 | 0.07 | Why? |
| Follow-Up Studies | 3 | 2019 | 17020 | 0.07 | Why? |
| Early Detection of Cancer | 1 | 2015 | 1956 | 0.07 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.06 | Why? |
| Europe | 1 | 2020 | 12702 | 0.06 | Why? |
| United States | 3 | 2021 | 46150 | 0.06 | Why? |
| Australia | 1 | 2017 | 6306 | 0.06 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.06 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.06 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.06 | Why? |
| Health Behavior | 1 | 2020 | 4449 | 0.06 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.06 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 13720 | 0.06 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.05 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.05 | Why? |
| Air Pollution | 1 | 2018 | 3504 | 0.05 | Why? |
| Nicaragua | 1 | 2018 | 71 | 0.05 | Why? |
| Schools | 3 | 2021 | 4187 | 0.05 | Why? |
| Outpatients | 1 | 2012 | 3417 | 0.05 | Why? |
| India | 1 | 2017 | 11875 | 0.05 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.05 | Why? |
| Personal Protective Equipment | 2 | 2020 | 15978 | 0.05 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.05 | Why? |
| Stochastic Processes | 1 | 2020 | 369 | 0.04 | Why? |
| Hemagglutinins | 1 | 2019 | 143 | 0.04 | Why? |
| Control Groups | 1 | 2018 | 49 | 0.04 | Why? |
| Cities | 2 | 2020 | 4937 | 0.04 | Why? |
| Viral Vaccines | 1 | 2019 | 7560 | 0.04 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2020 | 53120 | 0.04 | Why? |
| Breast Neoplasms | 1 | 2015 | 3633 | 0.04 | Why? |
| Poisson Distribution | 1 | 2018 | 348 | 0.04 | Why? |
| Odds Ratio | 2 | 2019 | 5861 | 0.04 | Why? |
| Vitamin D | 1 | 2012 | 2904 | 0.04 | Why? |
| Hospital Mortality | 2 | 2020 | 22087 | 0.04 | Why? |
| Treatment Adherence and Compliance | 1 | 2018 | 194 | 0.04 | Why? |
| Antineoplastic Protocols | 1 | 2015 | 25 | 0.04 | Why? |
| Organ Specificity | 1 | 2020 | 1070 | 0.04 | Why? |
| Socioeconomic Factors | 3 | 2018 | 8495 | 0.04 | Why? |
| Mandatory Reporting | 1 | 2017 | 140 | 0.04 | Why? |
| Holidays | 1 | 2018 | 311 | 0.04 | Why? |
| Radiotherapy, Adjuvant | 1 | 2015 | 180 | 0.04 | Why? |
| Malaysia | 1 | 2019 | 1116 | 0.04 | Why? |
| Anxiety | 1 | 2020 | 17311 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2020 | 6740 | 0.03 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2018 | 511 | 0.03 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.03 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Markov Chains | 1 | 2015 | 502 | 0.03 | Why? |
| Vietnam | 1 | 2018 | 1665 | 0.03 | Why? |
| Genes, Viral | 1 | 2018 | 1428 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2019 | 9893 | 0.03 | Why? |
| Quality-Adjusted Life Years | 1 | 2015 | 511 | 0.03 | Why? |
| Chemotherapy, Adjuvant | 1 | 2015 | 606 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Ferrets | 1 | 2018 | 1201 | 0.03 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.03 | Why? |
| Mammography | 1 | 2015 | 410 | 0.03 | Why? |
| Israel | 1 | 2020 | 2751 | 0.03 | Why? |
| Demography | 1 | 2018 | 1660 | 0.03 | Why? |
| Hypocalcemia | 1 | 2012 | 120 | 0.03 | Why? |
| Asia | 1 | 2018 | 2399 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| New York | 1 | 2018 | 2488 | 0.03 | Why? |
| Sex Distribution | 1 | 2017 | 2083 | 0.03 | Why? |
| Postoperative Period | 1 | 2012 | 651 | 0.03 | Why? |
| Hand Hygiene | 1 | 2020 | 1493 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Feasibility Studies | 1 | 2019 | 3467 | 0.02 | Why? |
| Swine | 1 | 2018 | 3352 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Commerce | 1 | 2017 | 1109 | 0.02 | Why? |
| Calcium | 1 | 2012 | 708 | 0.02 | Why? |
| Attitude to Health | 1 | 2020 | 2002 | 0.02 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Risk | 1 | 2019 | 5288 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Area Under Curve | 1 | 2012 | 2564 | 0.02 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.02 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.02 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Acute Disease | 1 | 2016 | 6029 | 0.02 | Why? |
| Preoperative Care | 1 | 2012 | 1515 | 0.01 | Why? |
| Immunotherapy | 1 | 2015 | 2421 | 0.01 | Why? |
| Antigens, Viral | 1 | 2019 | 6298 | 0.01 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.01 | Why? |
| Air Pollutants | 1 | 2018 | 3110 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.01 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2012 | 7220 | 0.01 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.01 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.01 | Why? |
| Comorbidity | 1 | 2016 | 34796 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |